Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial

Standard ILD Diagnostic Pathway · Не указано

ID реестра
NCT07482917
Фаза
Не указано
Статус
Набор идет
Препарат / вмешательство
Standard ILD Diagnostic Pathway
Спонсор
Hospital de Granollers
Начало
2026-03-09
Набор участников
92
Центры
1

Об исследовании

The OPTIMIZE-ILD-1 trial is a prospective, randomized, open-label clinical trial designed to evaluate the impact of a coordinated diagnostic pathway on patients with suspected interstitial lung disease (ILD). In routine clinical practice, diagnostic workflows for ILD are frequently fragmented, involving multiple independent appointments that can lead to significant delays and increased burden for patients and caregivers. This study compares the standard diagnostic pathway against an optimized circuit where core diagnostic procedures-such as high-resolution CT, pulmonary function tests, and laboratory panels-are pre-bundled and scheduled within a coordinated and compressed timeframe. All eligible patients referred for suspected ILD are included consecutively to ensure a pragmatic, real-wor

Открыть NCT07482917 на ClinicalTrials.gov →

Медицинская оговорка. Эта страница обобщает публичные данные исследования NCT07482917 только для информации. Это не медицинская рекомендация, не одобрение и не предложение участия. Проверяйте детали на ClinicalTrials.gov и у квалифицированного врача.